摘要
目的 应用光敏剂作为放射增敏剂探索其放射增敏作用。方法 应用血卟啉衍生物癌光啉 (PSD 0 0 7)配合放射治疗对 194例食管癌做前瞻性随机分组研究 ,放射增敏组及单纯放射组各97例。 2个组均采用60 Co或直线加速器常规照射 ,放射增敏组剂量为 6 5～ 73Gy ,单纯放射组为 6 5～75Gy。随访率为 97.4%。 结果 中位生存期放射增敏组为 2 6 .7个月 ,单纯放射组为 14.9个月 (P<0 .0 5 )。 1,3,5年生存率放射增敏组分别为 75 .3% ,38.1%及 2 0 .6 % ,单纯放射组分别为 5 4.6 % ,2 5 .8%及 10 .3% (P <0 .0 5 )。结论 癌光啉配合放射治疗食管癌可提高疗效 。
Objective To study the radiosensibility of photosensitizer PSD 007.Methods From July 1987 to July 1992,photosensitizer PSD 007 was used as radiosensitizer combined with radiation to treat esophageal cancer. A total of 194 cases were randomized into two groups,97cases were treated by radiotherapy combined with photosensitizer. As control group the other 97 cases were treated by radiotherapy alone. The radiation dose of 2 Gy per day and 5 times per week was adminitered to a total dose of 65～75 Gy. Total dose of PSD 007 varied from 300 to 1?000 mg (average 705.3 mg). The follow up rate was 97.4%.Results The median survival time for photosensitizer group and control group were 26.7 and 14.9 months, respectively(P<0.05). The 1 ,3 ,5 year survival rates of photosensitizer group were 75.3%,38.1% and 20.6%,and those of control group were 54.6%,25.8% and 10.3%(P<0.05). The toxic effect did not affect the treatment.Conclusions It is suggested that photosensitizer PSD-007 could increase the radiosensibility and improve the survival rate.
出处
《中华放射肿瘤学杂志》
CSCD
北大核心
2000年第1期26-28,共3页
Chinese Journal of Radiation Oncology
关键词
癌光啉
食管肿瘤
放射增敏
远期疗效
PSD-007
Esophageal neoplasms/therapy
Radiosensibility
